Jump to content
International Collaboration For Dog Health And Welfare. Join Us.

Neuronal Ceroid Lipofuscinosis 5 (NCL5)

General

Disease Name
Neuronal Ceroid Lipofuscinosis 5 (NCL5)
OMIA
1482
Gene Name
CLN5
Mutation
c.619C>T
Mutation 2
c.934_935delAG
OMIM
256731
Disease Code
NCL5
Test Type
Genetic Disease/Disorder
Details
The Neuronal ceroid lipofuscinosis (NCLs) are a group of inherited neurodegenerative diseases characterized by accumulation of autofluorescent cytoplasmic antibodies within cells of the nervous system. Affected dogs typically exhibit a condition of cerebellar dysfunction in which voluntary muscular movements tend to result in loss of control and coordination. Symptoms (18-24 months of age): vision loss, poor coordination, behavioural changes (aggression, hyperactivity and dementia)
Details 2
The Neuronal ceroid lipofuscinosis (NCLs) are a group of inherited neurodegenerative diseases characterized by accumulation of autofluorescent cytoplasmic antibodies within cells of the nervous system. Affected dogs typically exhibit a condition of cerebellar dysfunction in which voluntary muscular movements tend to result in loss of control and coordination. Symptoms (18-24 months of age): vision loss, poor coordination, behavioural changes (aggression, hyperactivity and dementia)
Published
Melville, SA., Wilson, CL., Chiang, CS., Studdert, VP., Lingaas, F., Wilton, AN. : A mutation in canine CLN5 causes neuronal ceroid lipofuscinosis in Border collie dogs. Genomics 86:287-94, 2005. Pubmed reference: 16033706. DOI: 10.1016/j.ygeno.2005.06.005.
Published 2
Gilliam, D., Kolicheski, A., Johnson, G.S., Mhlanga-Mutangadura, T., Taylor, J.F., Schnabel, R.D., Katz, M.L. : Golden Retriever dogs with neuronal ceroid lipofuscinosis have a two-base-pair deletion and frameshift in CLN5. Mol Genet Metab 115:101-9, 2015. Pubmed reference: 25934231. DOI: 10.1016/j.ymgme.2015.04.001.
Body/System/Process
Metabolic
Inheritance
AR
Gene Name Text
ceroid-lipofuscinosis, neuronal 5
×
×
  • Create New...

Important Information

By using this site, you agree to our Terms of Use.